Cemdisiran Recruiting Phase 2 Trials for Berger Disease / IgA Nephropathy (IgAN) / IgA Glomerulonephritis Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03841448A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)